Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance, not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different "hot spots," were gain of function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole resistance but that they can also confer a selective advantage under host conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.](https://figures.cochat.ai/paper-figures/69b6baffc71c4842aa873ef304106b27/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-2.jpg)

![Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).](https://figures.cochat.ai/paper-figures/ac16b99890e140cf9efad3769d9335b6/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-4.jpg)
![Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.](https://figures.cochat.ai/paper-figures/22fe62baf08b4a8880e792810b2a746e/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-5.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors also indicate that the altered cellular sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via facilitated diffusion [213].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other cases of induced cross-resistance to azole drugs in C. glabrata were related to resistance against both azoles and amphotericin B [198,199,212] and related to prochloraz (an agricultural antifungal).”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BPY41 exhibited mitochondrial dysfunction”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“however, it is not dependent on the presence of GOF mutations in *CgPDR1* ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784 · cited 1×
“efflux pumps (for review, see [7]).”
Self-citationThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“mutations in genes involved in antibiotic resistance can be beneficial in the fitness of pathogenic bacteria [30,31].”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“The consensus motif is named PDRE (for pleiotropic drug resistance element) and is present in several ABC-transporter gene promoters such as PDR5, SNQ2 and YOR1 [25].”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472 · cited 1×
“Restoration of fitness in drugresistant bacteria is often associated with the emergence of compensatory mutations [29].”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“during patient treatment [4–6].”
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 2×
“In bacteria, antimicrobial resistance is often associated with fitness costs and thus results in a competitive disadvantage against otherwise drug-susceptible bacteria within the host [28].”
BackgroundA nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343 · cited 1×
“. CgPdr1p acts as nuclear receptor by directly binding to diverse drugs and xenobiotics, such as azoles, to activate expression of efflux pumps genes resulting in multidrug resistance”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 5×
“glabrata was performed as previously described [10].”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 201–291 of 291
Mechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Self-citationTian, Y., Zhuang, Y., Chen, Z., Mao, Y., Zhang, J., Lu, R., & Guo, L. (2020) · Microbiological Research · doi:10.1016/j.micres.2020.126519 · Cited by 7
Edlind, T., & Katiyar, S. K. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00721-22 · Cited by 8
“(15), and 17 exhibited unaltered H2O2 susceptibility relative to their FLC-susceptible parents.”
BackgroundEvolution of regulatory networks inCandida glabrata: learning to live with the human host
Roy, S., & Thompson, D. A. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov087 · Cited by 9
“Gain-of-function mutations in CgPdr1 not only enhances antifungal resistance but also increases virulence (Ferrari et al. 2009).”
BackgroundMicroevolution of Candida glabrata (Nakaseomyces glabrata) during an infection
López-Marmolejo, A. L., Hernández-Chávez, M. J., Gutiérrez‐Escobedo, G., Herrera-Basurto, M. S., Mora-Montes, H. M., Peñas, A. D. L., & Castaño, I. (2024) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2024.103891 · Cited by 7
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., Cabrera, N., İlkit, M., Desai, J. V., Gabaldón, T., Shor, E., & Perlin, D. S. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae035 · Cited by 7
“Interestingly, studies have shown that FLZR C. glabrata isolates are more virulent in the context of systemic infections (19), less effectively phagocytosed by macrophages, and more strongly adherent to epithelial cells compared to susceptible isolates (19, 20).”
Kumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 7
Ibe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 7
“GoF mutation in C. glabrata, Pdr1, which also regulates CDR1 , has also been linked to fluconazole resistance [25].”
Pellaton, N., Sanglard, D., Lamoth, F., & Coste, A. T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.859439 · Cited by 8
Self-citationSanglard, D. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0055-9 · Cited by 7
“glabrata compromised the ability of ABC transporters to be upregulated in clinical isolates [69–72].”
BackgroundSelf-citationUsher, J., Thomas, G., & Haynes, K. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov091 · Cited by 6
“…gene function in pathogenic fungi, have taken a candidate gene or directed approach, however these approaches are limited by our knowledge of the pathways and/or proteins involved (Calcagno et al., 2003; Ferrari et al., 2009; Gabaldón et al., 2013; Juárez-Cepeda et al., 2015; Roetzer et al., 2008).”
BackgroundTian, Y., Gao, N., Ni, Q., Mao, Y., Dong, D., Huang, X., Jiang, C., Li, Z., Zhang, L., Wang, X., et al. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy038 · Cited by 6
Tantivitayakul, P., Lapirattanakul, J., Kaypetch, R., & Muadcheingka, T. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.01.006 · Cited by 8
The Fungal Cell Death Regulator czt-1 Is Allelic to acr-3
Gonçalves, A. P., McCluskey, K., Glass, N. L., & Videira, A. (2019) · Journal of Fungi · doi:10.3390/jof5040114 · Cited by 6
“crassa [22] and have been associated with drug resistance in various animal and plant pathogens [20,21,23].”
BackgroundResultMerdan, O., Şişman, A. S., Aksoy, S. A., Kızıl, S., Tüzemen, N. Ü., Yılmaz, E., & Ener, B. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00776-22 · Cited by 7
“glabrata isolates, indicating no relationship to azole resistance as shown in the past studies (36, 37).”
ResultTumbarello, M., Posteraro, B., Trecarichi, E. M., & Sanguinetti, M. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.243 · Cited by 7
Self-citationCaracterización de Candida spp. aisladas a partir de urocultivos en la ciudad de Medellín
Duque, C., Sánchez, D. M., Gaviria, Á. M., Acosta, A. V., Gómez, B. L., Gómez, O. M., Giraldo, Á., & Hernández, O. (2020) · Infectio · doi:10.22354/in.v24i4.879 · Cited by 4
Hwang, I. J., Kwon, Y. J., Lim, H. J., Hong, K. H., Lee, H., Yong, D., Won, E. J., Byun, S. A., Lee, G. Y., Kim, S. H., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00883-24 · Cited by 6
Zhang, Y., Gong, S., Xiong, K., Yu, X., Mo, X., Su, C., & Lü, Y. (2024) · mSphere · doi:10.1128/msphere.00910-24 · Cited by 5
Fattouh, N., Husni, R., Finianos, M., Bitar, I., & Khalaf, R. A. (2024) · Mycoses · doi:10.1111/myc.13750 · Cited by 5
“13 The amino acid substitution S343F in Pdr1 is the result of a gain- of-function mutation that activates the efflux pumps Cdr1, Pdr1 and/or Snq2 which could reduce azole susceptibility in C. glabrata .”
BackgroundInfluentialMolecular Detection of Resistance to Azole Components
Posteraro, B., Vella, A., Carolis, E. D., & Sanguinetti, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_24 · Cited by 5
Self-citationThe Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_29-1 · Cited by 7
Antifungal Resistance: Cellular and Molecular Mechanisms
Araújo, R., & Espinel‐Ingroff, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_7 · Cited by 6
Saha, D., Gregor, J. B., Hoda, S., Eastman, K. E., Gutierrez-Schultz, V. A., Navarrete, M., Wisecaver, J. H., & Briggs, S. D. (2024) · mSphere · doi:10.1128/msphere.00524-24 · Cited by 4
“A common mechanism of altering azole resistance in C. glabrata involves the upregulation of drug efflux pumps, such as CDR1 , PDH1 , and SNQ2 , facilitated by the zinc cluster transcription factor Pdr1 (28, 29, 31, 54, 55).”
Induction of Antifungal Tolerance Reveals Genetic and Phenotypic Changes in Candida glabrata
Chedraoui, C., Fattouh, N., Hachem, S. E., Younes, M., & Khalaf, R. A. (2025) · Journal of Fungi · doi:10.3390/jof11040284 · Cited by 5
“The most common mutations conferring resistance to azoles occur in PDR1 ; therefore, a positive correlation has been observed with increased resistance to azoles and virulence in murine models [60,61].”
Verma, S., Tilak, R., Singh, G., Singh, S., Kumari, A., Rudramurthy, S. M., Spruijtenburg, B., Meis, J. F. G. M., de Groot, T., Meijer, E. F. J., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf420 · Cited by 4
Eknure, C., Agarwal, A. P., Bachhav, Y. G., & Kumar, M. S. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04671-6 · Cited by 5
“Figure 3 illustrates how increased efflux activity reduces intracellu - lar drug concentrations while elevating extracellular levels, thereby reducing the drug’s efficacy (Ferrari et al. 2009).”
Jann, J., Gagnon‐Arsenault, I., Pageau, A., Dubé, A. K., Fijarczyk, A., Durand, R., & Landry, C. R. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003645 · Cited by 5
“…mutations in PDR1 lead to overexpression of downstream targets, including ABC efflux pump genes like CDR1 , CDR2 , and SNQ2 , conferring broad-spectrum drug resistance in both the model yeast Saccharomyces cerevisiae and the human pathogen Nakaseomyces glabratus ( Candida glabrata ) [39,40].”
Les pompes à efflux en mycologie médicale : mécanismes moléculaires et perspectives thérapeutiques
Kouidhi, B., Gaied, M. B., Mhadhebi, L., Bakhrouf, A., & Bouraoui, A. (2010) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.07.007 · Cited by 5
Döğen, A., Durukan, H., Güzel, A. B., Oksüz, Z., Kaplan, E., Serin, M. S., Serin, A., Emekdaş, G., Aslan, G., Tezcan, S., et al. (2013) · Mikrobiyoloji Bulteni · doi:10.5578/mb.4302 · Cited by 5
Narayanan, A., Shaji, A. A., Pullepu, D., Bhattacharya, J., & Sanyal, K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00081 · Cited by 3
Luca, D. G. D., Alexander, D. C., Dingle, T. C., Dufresne, P. J., Fuller, J., German, G. J., Haldane, D. J. M., Hoang, L., Jiao, L., Kus, J. V., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01803-25 · Cited by 3
“Specific regions of PDR1 , referred to as the inhibitory domain (ID; 312–382 aa), middle homology region (MHR; 539–632 aa), and transcriptional activation domain (TAD; 800–1107 aa), are predictive of azole resistance (16).”
Sousa, G., Correia, I., & Bezerra, A. R. (2026) · Microorganisms · doi:10.3390/microorganisms14020273 · Cited by 3
“This overexpression was caused by the hyperactivity of the transcription factor PDR1 through gain-of-function mutations (R376W, D1026, T588A, E1083Q, Y584C, L280F, P822L) [86].”
Eliaš, D., Hervay, N. T., Černáková, L., & Gbelská, Y. (2024) · Journal of Fungi · doi:10.3390/jof10100669 · Cited by 3
“Gain-of-function (GOF) mutations in the transcription factor Cg Pdr1p induce the expression of ABC efflux pumps and the MFS transporter CgQDR2 [10,11].”
BackgroundResistance to Antifungal Drugs
Sanglard, D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_9 · Cited by 4
Self-citationImmunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant Candida Species
Beyda, N. D., Regen, S., Lewis, R. E., & Garey, K. W. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0132-3 · Cited by 3
“glabrata, these adaptations have been associated with virulence of experimental isolates in animal infection models [20, 21].”
BackgroundAbbes, S., Amouri, I., Sellami, H., Neji, S., Trabelsi, H., Cheikhrouhou, F., Makni, F., Ranque, S., & Ayadi, A. (2014) · Therapies · doi:10.2515/therapie/2014059 · Cited by 3
Host-Fungal Interactions: Pathogenicity versus Immunity
Tavanti, A., Naglik, J. R., & Osherov, N. (2012) · International Journal of Microbiology · doi:10.1155/2012/562480 · Cited by 5
“Collectively, this data in addition to the available literature support the hypothesis that efflux pumps are an important, but not exclusive, determinant of fungal biofilm resistance to azoles [143, 145].”
BackgroundResultBatista, C. S. P., Rivera, A., Alvarez Albarran, M. T., Rubio, M., Belen-Figas, I., Lopez-Querol, C., Miró, E., Navarro, F., & Sanchez-Reus, F. (2025) · Journal of Fungi · doi:10.3390/jof11110808 · Cited by 2
Conway, T. P., Vu, B. G., Beattie, S. R., Krysan, D. J., & Moye-Rowley, S. (2024) · mSphere · doi:10.1128/msphere.00792-24 · Cited by 3
Gador‐Whyte, A., Rhodes, J. L., Farrer, R. A., Bakker, S., Wirth, W., Coldbeck-Shackley, R. C., Howden, B. P., Kwong, J. C., Sherry, N. L., & Seemann, T. (2026) · Microbial Genomics · doi:10.1099/mgen.0.001710 · Cited by 2
“Where known resistance ‘hotspots’ occur in fAMR genes, for instance, in FKS1 in many yeasts [116] and PDR1 in N. glabratus [117], the location of inferred amino acid substitutions could be incorporated as supporting evidence for a mutation as a resistance determinant.”
Šimoničová, L., & Moye-Rowley, S. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3155-3_11 · Cited by 2
Kubica, S., Szulińska, W., Kruszniewska‐Rajs, C., Kimsa‐Dudek, M., Olender, A., Bogut, A., Szukała, M., Dąbrowski, W., Pietrzak, D., Gagoś, M., et al. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01298-w · Cited by 2
“This overexpression is commonly associated with mutations in the PDR1 gene, which encodes a transcription factor essential for the expression of the CDR1 and CDR2 genes (Ferrari et al. 2009; Tsai et al. 2010).”
Fungal Drug Resistance: Azoles
Lopez-Ribot, J. L., Wiederhold, N. P., & Patterson, T. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_27 · Cited by 3
The Impact of Antifungal Drug Resistance in the Clinic
Lewis, R. E., & Kontoyiannis, D. P. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch23 · Cited by 2
Membrane et paroi fongiques : des rôles clés dans la résistance aux antifongiques
Garnaud, C., & Cornet, M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30062-9 · Cited by 6
Candida glabrata Hst1-Rfm1-Sum1 complex evolved to control virulence-related genes
Vázquez-Franco, N., Gutiérrez‐Escobedo, G., Juárez‐Reyes, A., Orta‐Zavalza, E., Castaño, I., & Peñas, A. D. L. (2021) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2021.103656 · Cited by 3
Nonantifungal Clinical Drug Interventions and Human-Commensal Fungi: What are we Selecting?
Hull, C. M., & Purdy, N. J. (2013) · Future Microbiology · doi:10.2217/fmb.13.45 · Cited by 2
Transcriptional Regulation of Azole Antifungal Resistance and Tolerance in Candida Glabrata
Caudle, K. E. (2010) · doi:10.21007/etd.cghs.2010.0045 · Cited by 4
“cerevisiae, single point mutations in the regulatory domain of CgPDR1 make this transcription factor hyperactive resulting in high-level transcription of CgCDR1 and CgPDH1 as well as increased resistance to azoles (68, 210, 212, 215).”
BackgroundInfluentialMechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Hybrid adaptation is hampered by Haldane’s sieve
Bautista, C., Gagnon-Arsenault, I., Utrobina, M., Fijarczyk, A., Bendixsen, D. P., Stelkens, R., & Landry, C. R. (2023) · doi:10.1101/2023.12.15.571924 · Cited by 2
Implication of genotypes for prognosis of Candida glabrata bloodstream infections
Chen, P., Huang, Y., Chuang, Y., Wang, J., Sheng, W., Chen, Y., & Chang, S. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae200 · Cited by 2
“8,9,11,12,22,30 Further, adherence rates of each diagnostic and treatment measure were suboptimal in our cohort, but comparable to those in previous studies.”
BackgroundResultRor, S., Stamnes, M. A., & Moye-Rowley, S. (2024) · mSphere · doi:10.1128/msphere.00425-24 · Cited by 1
“This behavior is similar to that seen for the Candida glabrata Pdr1 protein in which many different mutations have been mapped to the C-terminus of this protein that cause the resulting mutant Pdr1 protein to behave as a constitutively active regulator of gene expression (20).”
ResultMutations across Diverse Domains of CjXDR1 Lead to Multidrug Resistance in Clarireedia jacksonii
Zhang, H., Jin, P., Kong, Y., Jia, C., Qiao, P., Dong, Y., Zhou, Y., Hu, J., Yang, Z., & Jung, G. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c05106 · Cited by 1
Uncovering actionable trade-offs of antifungal resistance in a yeast pathogen
Nunez‐Rodriguez, J. C., Schikora-Tamarit, M. À., & Gabaldón, T. (2026) · Molecular Systems Biology · doi:10.1038/s44320-025-00185-3 · Cited by 1
“This suggests that although most strains exhibit trade-offs, they do not always impact multifactorial host competitiveness or infective capacity (Ferrari et al, 2009; Vale-Silva et al, 2013; Arastehfar et al, 2024).”
Gim3 buffers and potentiates de novo mutations that affect fluconazole susceptibility in yeast
Tawfeeq, M. T., Konstantinidis, D., Iraizos, A. L. R., Genechten, W. V., Vreys, J., Vermeersch, L., Voordeckers, K., Dijck, P. V., & Verstrepen, K. J. (2026) · EMBO Reports · doi:10.1038/s44319-026-00702-x · Cited by 1
“Mitochondrial dysfunction activates Pleiotropic Drug Resistance (PDR) regulators, increasing ef fl ux and modulating azole response (Ferrari et al, 2009; Tsai et al, 2006; Hallstrom and Moye-Rowley, 2000).”
Candida glabrata YPK2 is a multidrug susceptibility locus
Šimoničová, L., Conway, T. P., Krüger, T., Brakhage, A. A., & Moye-Rowley, S. (2026) · Genetics · doi:10.1093/genetics/iyag176 · Cited by 1
“A large number of clinical isolates have yielded the consistent finding of substitution mutations in a Zn 2 Cys 6 -DNA-binding domain-containing transcription factor called Pdr1 (Vermitsky and Edlind 2004; Tsai et al. 2006; Ferrari et al. 2009).”
ATP-driven dynamics and itraconazole binding of the drug efflux pump Cdr1 from Candida glabrata
Pata, J., Wiseman, B., Zarkadas, E., Baccouch, R., Samrouth, N., Desbois, C., Moissonnier, L., Moréno, A., Banerjee, A., Aguero, S., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00920-y · Cited by 1
Balazfyova, Z., Hervay, N. T., & Gbelská, Y. (2013) · Yeast · doi:10.1002/yea.2941 · Cited by 1
“…of point mutations occurring in transcriptional regulators of these effector genes (Carvajal et al., 1997; Nourani et al., 1997; Simonics et al., 2000; Le Crom et al., 2002; Mamnun et al., 2002; Coste et al., 2004; Tsai et al., 2006; Fardeau et al., 2007; Ferrari et al., 2009; Morschhäuser, 2010).”
BackgroundInfluentialWei, K., Arlotto, M., Overhulse, J. M., Dinh, T., Zhou, Y., Dupper, N. J., Yang, J., Kashemirov, B. A., Dawi, H., Garnaud, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202404260 · Cited by 2
Goffa, E., Bialková, A., Batova, M., Džugasová, V., & Šubík, J. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00702.x · Cited by 1
“glabrata clinical isolates recovered from different patients worldwide (Tsai et al., 2006; Berila et al., 2009; Ferrari et al., 2009).”
BackgroundInfluentialMultidrug Resistance in Fungi: The Role of Pleiotropic Drug Resistance Genes
Sharma, S., & Ganesan, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_8 · Cited by 1
In the Crossroad Between Drug Resistance and Virulence in Fungal Pathogens
Cavalheiro, M., & Teixeira, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-030-00683-9_7 · Cited by 1
Conway, T. P., Šimoničová, L., & Moye-Rowley, S. (2024) · Genetics · doi:10.1093/genetics/iyae115 · Cited by 2
“Furthermore, past work has shown that GOF mutations can occur in either the CRD or TAD of the Pdr1 protein, both resulting in constitutively active Pdr1 forms (Ferrari et al. 2009).”
InfluentialMechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Cell individuality in adhesin expression of Candida glabrata
Halliwell, S. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 1
Genome dynamics and virulence in the human pathogen Candida glabrata
Ahmad, K. M. (2014) · Lund University Publications (Lund University)
Mechanisms of Multidrug Resistance in Fungal Pathogens
Ferrari, S., & Sanglard, D. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_15
Self-citationFungal Drug Resistance: Azoles
Lopez-Ribot, J. L., & Patterson, T. F. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_26
Structural and functional study of the nitrate transporter, NrtA
Silva, D., & Nunes, I. R. (2013) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Robledo-Leal, E., Adame-Rodríguez, J. M., González, G. M., & Aréchiga‐Carvajal, E. T. (2012) · RESPYN Revista de Salud Pública y Nutrición
Pós-Graduação, P. D., Eduardo, C., & Teixeira, C. (2014) · Cited by 1
Insight into the Kluyveromyces lactis Pdr1p regulon
Hervay, N. T., Konecna, A., Balazfyova, Z., Svrbicka, A., & Gbelská, Y. (2016) · Canadian Journal of Microbiology · doi:10.1139/cjm-2016-0220
“Extensive analysis of the suite of Pdr1p-regulated genes were accomplished in S. cerevisiae (DeRisi et al. 2000; Devaux et al. 2001; Lucau-Danila et al. 2005, Fardeau et al. 2007) and C. glabrata (Vermitsky et al. 2006; Ferrari et al. 2009; Tsai et al. 2010).”
MethodMental Health Outcomes in Survivors of Childhood Cancer
Nachman, A. (2016) · TSpace (University of Toronto)
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
The Research Progress on Occurrence of Candida Drug Resistance
付, 婉. (2017) · Advances in Microbiology · doi:10.12677/amb.2017.64013
Mohamed, N. A. N. (2020) · UWC Research Repository (University of the Western Cape)
Multidrug Resistance Transcriptional Regulatory Networks in Candida
Rogers, P. D., & Barker, K. S. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch25 · Cited by 1
(2009) · Yeast · doi:10.1002/yea.1624
Bohner, F. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12031
Klimova, N. G., Patel, H., Devaux, F., & Turcotte, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.25.645289
Williams, C. C., & Usher, J. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02522-24
“Our findings corroborate previous research, which has shown that different CgPDR1 + results in unique azole susceptibility profiles (32, 36, 37, 39, 44–47 , 50).”
InfluentialPinheiro, M. J. F., Parker, J. E., Ferreira, M. T., Fernandes, F., & Mira, N. P. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03344-25
“…by Pdr1-dependent responses in azole resistance in N. glabratus , a few clinical strains that encode PDR1 “wild-type” alleles (that is, alleles identical to those encoded by azole susceptible strains) have been identified, including ISTB218, which is at the center of this work (13, 14, 17–19).”
Shathan, A., Najjar, A., Jourk, A., & Noor, S. O. (2026) · Microorganisms · doi:10.3390/microorganisms14040795 · Cited by 1
“The natural reduced azole sensitivity of N. glabratus and its remarkable ability to acquire resistance under selection pressure confounds treatment results [6].”
Characterization of the nuclear RNase P of Candida glabrata and improvement of genome editing tools
Dahman, Y. (2018) · theses.fr (ABES) · doi:10.70675/82cd4f14z1fe3z42dczaf17z642b31bd4dd1
“The resistance of C. glabrata clinical isolates to azoles is amplified by the acquisition of several mutations in the PDR1 gene leading to its hyperactivity (Ferrari et al. 2009).”
BackgroundDiploidy alters the path of fluconazole adaptation in Candida glabrataPreprint
Galeota-Sprung, B., Fernandez, A., Wright, C., Tejada, R. S., & Sniegowski, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.727327
“Second, C. glabrata easily acquires mutations to PDR1 that drive resistance to fluconazole [15], [16], [17], [18] .”
Gador‐Whyte, A., Seemann, T., Judd, L. M., Horan, K., Lacey, J. A., Traven, A., Daniel, D., Guérillot, R., Giulieri, S. G., Vogrin, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733717
Caracciolo, M., Caracciolo, S. A., Stagno, M. F., Pellicano, S., Ripepi, A., Pellicano, N., Scopelliti, C., Serranò, A., Loddo, A., & Scala, S. L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1937682
Caracciolo, M., Caracciolo, S. A., Stagno, M. F., Papola, C., Pellicano, S., Nicolò, G. M., D’Aleo, F., Ripepi, A., Scopelliti, C., Principe, L., et al. (2026) · Journal of Fungi · doi:10.3390/jof12110802
Choudhary, A. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-05275-w
“…resistance rapidly through gain-of-function mutations in the transcription factor PDR1 that upregulate the ABC transporters Cdr1, Pdh1/ Cdr2 and Snq2 (Whaley et al. 2017; Ferrari et al. 2009 ); MSH2 mismatch-repair defects generate hypermutator phenotypes in some lineages (Healey and Perlin 2018).”
Piva, E. (2012) · Americanae (AECID Library)
Metadata
- Authors
- Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- GATC Biotech (Germany) (DE)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Sanglard, Dominique
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-16
- Volume
- 5
- Issue
- 1
- Pages
- e1000268
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2607542
- OpenAlex
- W2133189384
- Cited by
- 295
- References
- 46
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 19 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 25 · 2017: 19 · 2016: 17 · 2015: 12 · 2014: 22 · 2013: 18 · 2012: 14
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, gain-of-function mutations, azole resistance, antifungal resistance, virulence, ABC transporters, transcription factors, clinical isolates, host fitness, trans-acting regulation
- MeSH terms
- Animals, Candidiasis, Female, Humans, Mice, Inbred BALB C, Mutation, Transcription Factors, Virulence, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Amino Acid Substitution, Drug Resistance, Fungal, Candida glabrata, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.